Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis

Chang, Kuang-Hsi; Chung, Chi-Jung; Lin, Cheng‐Li; Sung, Fung‐Chang; Wu, Trong-Neng; Kao, Chia‐Hung

doi:10.1007/s11357-013-9608-x

Cited by 82 publications

(56 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a genetic point of view, an association of the Apo E4 allele with low BMD has been repeatedly reported, yet results are conflicting [1, 35]. In the present study, serum vitamin D levels were lower among participants who developed cognitive impairment; nevertheless, the association of low BMD with cognitive impairment was independent of vitamin levels.…”

Section: Discussioncontrasting

confidence: 54%

“…In fact, dementia has been detected in 14–20 % of older subjects; approximately 4.6 million people are diagnosed with dementia each year, with a twofold increase in the disease prevalence every 20 years [1]. By 2020, the population with a diagnosis of dementia is expected to increase to 42.3 million worldwide, and to 81.1 million by 2040 [1]. The incidence of dementia disorders increases exponentially beyond the age of 65.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, there is evidence of an increased risk of dementia in subjects with diagnosis of osteoporosis or osteoporotic fractures in Asian populations [1]; however, there are relevant racial differences in bone mass, so that Asian women have lower bone mass than Caucasian [9]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bone Mineral Density and Cognitive Decline in Elderly Women: Results from the InCHIANTI Study

et al. 2015

View full text Add to dashboard Cite

Osteoporosis and cognitive impairment, which are highly prevalent conditions in elderly populations, share several risk factors. This study aims at evaluating the association of bone mineral density (BMD) with prevalent and incident cognitive impairment after a 3-year follow-up. We studied 655 community-dwelling women aged 65+ participating in the InCHIANTI study, who had been followed for 3 years. Total, trabecular, and cortical BMD were estimated by peripheral quantitative computed tomography using standard transverse scans at 4 and 38 % of the tibial length. Cognitive performance was evaluated using the Mini-Mental State Examination and the Trail Making Tests (TMT) A and B; a MMSE score <24 was adopted to define cognitive impairment. The TMT A–B score was calculated as the difference between TMT-A and TMT-B times (ΔTMT). The association of cognitive performance after 3 years with baseline indices of BMD was assessed by logistic and linear regression analyses. Cortical, but not trabecular, BMD was independently associated with incident cognitive impairment (OR 0.93, 95 % CI 0.88–0.98; P = 0.012), worsening cognitive performance (OR 0.96, 95 % CI 0.92–0.98; P = 0.039), and worsening performance in ΔTMT (OR 0.96, 95 % CI 0.92–0.99; P = 0.047). Increasing cortical BMD tertiles was associated with decreasing probability of incident cognitive impairment (P for linear trend =0.001), worsening cognitive performance (P = 0.013), and a worsening performance below the median value (P for linear trend <0.0001). In older women, low BMD might represent an independent and early marker of subsequent cognitive impairment. Physicians should assess and monitor cognitive performance in the routine management of elderly women with osteoporosis.

show abstract

Section: Discussioncontrasting

confidence: 54%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bone Mineral Density and Cognitive Decline in Elderly Women: Results from the InCHIANTI Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Recent studies have found PPIs to be associated with an increased risk of dementia 2122 Osteoporosis, one of the most common indications for calcium, has also been associated with increased risk of dementia 2324 In the present study, participants in their middle age taking PPIs or calcium showed poorer cognitive performance compared to non-takers.…”

Section: Discussionmentioning

confidence: 41%

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank

et al. 2016

View full text Add to dashboard Cite

ObjectiveTo investigate medications associated with cognitive function.DesignPopulation-based cross-sectional cohort study.SettingUK Biobank.ParticipantsUK Biobank participants aged 37–73 years who completed cognitive tests at the baseline visit in 2006–2010.Main outcome measuresCognitive test outcomes on verbal–numerical reasoning test (n=165 493), memory test (n=482 766) and reaction time test (n=496 813).ResultsMost drugs (262 of 368) were not associated with any cognitive tests after adjusting for age, gender, education, household income, smoking, alcohol status, psychostimulant/nootropic medication use, assessment centre, and concurrent diagnoses and medications. Drugs used for nervous system disorders were associated with poorer cognitive performance (antiepileptics, eg, topiramate breasoning(score) −0.65 (95% CI −1.05 to −0.24), bmemory(score) −1.41 (−1.79 to −1.04); antipsychotics, eg, risperidone breaction time(ms) −33 (−46 to −20), negative values indicate poor cognitive performance and vice versa). Drugs used for non-nervous system conditions also showed significant negative association with cognitive score, including those where such an association might have been predicted (antihypertensives, eg, amlodipine breasoning −0.1 (−0.15 to −0.06), bmemory −0.08 (−0.13 to −0.03), breaction time −3 (−5 to −2); antidiabetics, eg, insulin breaction time −13 (−17 to −10)) and others where such an association was a surprising observation (proton pump inhibitors, eg, omeprazole breasoning −0.11 (−0.15 to −0.06), bmemory −0.08 (−0.12 to −0.04), breaction time −5 (−6 to −3); laxatives, eg, contact laxatives breaction time −13 (−19 to −8)). Finally, only a few medications and health supplements showed association towards a positive effect on cognitive function (anti-inflammatory agents, eg, ibuprofen breasoning 0.05 (0.02 to 0.08), breaction time 4 (3, 5); glucosamine breasoning 0.09 (0.03 to 0.14), breaction time 5 (3 to 6)).ConclusionsIn this large volunteer study, some commonly prescribed medications were associated with poor cognitive performance. Some associations may reflect underlying diseases for which the medications were prescribed, although the analysis controlled for the possible effect of diagnosis. Other drugs, whose association cannot be linked to the effect of any disease, may need vigilance for their implications in clinical practice.

show abstract

“…Although osteoporosis is a major health burden in the elderly, treatments for this disease are far from ideal. Osteoporosis and Alzheimer’s disease (AD) are common chronic degenerative disorders which are strongly associated with advanced age [1,2,3]. AD is frequently associated with fractures and reduction in bone mineral density, even at early stages of disease when patients are still active [4,5,6], indicating that AD and osteoporosis may share conserved pathogenic mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling

Yang

Teguh

et al. 2016

IJMS

View full text Add to dashboard Cite

Osteoporosis and Alzheimer’s disease (AD) are common chronic degenerative disorders which are strongly associated with advanced age. We have previously demonstrated that amyloid beta peptide (Aβ), one of the pathological hallmarks of AD, accumulated abnormally in osteoporotic bone specimens in addition to having an activation effect on osteoclast (Bone 2014,61:164-75). However, the underlying molecular mechanisms remain unclear. Activation of NF-κB, extracellular signal-regulated kinase (ERK) phosphorylates, and calcium oscillation signaling pathways by receptor activator NF-κB ligand (RANKL) plays a pivotal role in osteoclast activation. Targeting this signaling to modulate osteoclast function has been a promising strategy for osteoclast-related diseases. In this study, we investigated the effects of Aβ on RANKL-induced osteoclast signaling pathways in vitro. In mouse bone marrow monocytes (BMMs), Aβ exerted no effect on RANKL-induced osteoclastogenesis but promoted osteoclastic bone resorption. In molecular levels, Aβ enhanced NF-κB activity and IκB-α degradation, activated ERK phosphorylation and stimulated calcium oscillation, thus leading to upregulation of NFAT-c1 expression during osteoclast activation. Taken together, our data demonstrate that Aβ enhances RANKL-induced osteoclast activation through IκB-α degradation, ERK phosphorylation, and calcium oscillation signaling pathways and that Aβ may be a promising agent in the treatment of osteoclast-related disease such as osteoporosis.

show abstract

Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis

Cited by 82 publications

References 39 publications

Bone Mineral Density and Cognitive Decline in Elderly Women: Results from the InCHIANTI Study

Bone Mineral Density and Cognitive Decline in Elderly Women: Results from the InCHIANTI Study

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank

Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling

Contact Info

Product

Resources

About